Enzymatica
2.04 SEK
+2.00 %
Less than 1K followers
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Enzymatica
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 61.3 | 111.2 | 57.2 | 49.0 | 50.9 | 45.6 | 53.9 |
| growth-% | 81.5 % | -48.5 % | -14.5 % | 4.0 % | -10.5 % | 18.3 % | |
| EBITDA | -41.7 | -12.1 | -45.2 | -68.2 | -48.1 | -52.1 | - |
| EBIT | -41.7 | -12.1 | -45.2 | -68.2 | -48.1 | -52.1 | -51.4 |
| Profit before taxes | -41.9 | -13.1 | -45.7 | -68.8 | -49.7 | -53.3 | -51.8 |
| Net income | -41.0 | -13.2 | -45.4 | -68.7 | -49.7 | -53.2 | -51.9 |
| EPS | -0.27 | -0.10 | -0.29 | -0.41 | -0.28 | -0.28 | -0.21 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -68.0 % | -10.8 % | -79.0 % | -139.4 % | -94.4 % | -114.2 % | |
| EBIT-% | -68.0 % | -10.8 % | -79.0 % | -139.4 % | -94.4 % | -114.2 % | -95.3 % |
| ROE | -34.4 % | -12.4 % | -36.3 % | -54.4 % | -64.9 % | -30.2 % | -41.8 % |
| ROI | -27.7 % | -8.2 % | -28.9 % | -39.4 % | -39.5 % | -27.2 % | -36.5 % |